The 3B Future Health Fund invests in early-stage healthcare companies, primarily in the US, Europe, and Israel, with a focus on oncology and rare diseases. Their strategy is to identify and support innovative technologies and solutions that address significant unmet patient needs.
67% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (67% of deals). Average disclosed round size is $47.3M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$3B
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Kainova Therapeutics | Series B | $32M | Feb 2026 |
 iOnctura | Series B | $80M | Jun 2024 |
 On Target Laboratories, Inc. | Series C | $30M | Nov 2023 |
Top Co-Investors
Schroders Capital2 shared
H.I.G. Growth1 shared
Elevate Ventures1 shared
Olympus Innovation Ventures1 shared
Panacea Venture1 shared
Investissement Quebec1 shared
Viva BioInnovator1 shared
adMare BioInnovations1 shared
M Ventures1 shared
INKEF Capital1 shared
Vi Partners1 shared
Last updated: 10 April 2026